Skip to main content
. 2020 Jun 30;105(5):723–728. doi: 10.1136/bjophthalmol-2020-316594

Figure 1.

Figure 1

Decision tree model used to calculate the incremental cost-effectiveness of human grading versus replacing initial grading undertaken by human graders (primary graders) with automated retinal image analysis systems (ARIAS).5 6 The clinical practice pathway as illustrated reflects the pathway and grading23 that was used in previous cost-effectiveness analyses.5 6 Non-referable retinopathy refers to human grades of no observable retinopathy (R0) and mild-to-moderate non-proliferative retinopathy (R1) and non-referable maculopathy (M0). Referable retinopathy refers to referable maculopathy (M1), moderate-to-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3) and ungradable images (U).8 9 DESP, Diabetic Eye Screening Programme; DR, diabetic retinopathy.